Search
Rilpivirine
go.drugbank.com/drugs/DB08864ApprovedInvestigationalRilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients.[A31328] It is a diarylpyrimidine derivative. … [A31329] The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potency and reduces the chance of resistance compared to other NNRTI's
Mixtures: ODEFSEY® 200 MG - 25 MG - 25 MG TABLETAS RECUBIERTAS, Odefsey® (200mg Emtricitabine/25mg Rilpivirine/25mg Tenofovir alafenamide) film coated tabletsCategories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesTesamorelin
go.drugbank.com/drugs/DB08869ApprovedInvestigationalLipodystrophy is a metabolic condition characterized by insulin resistance, fat redistribution, and hyperlipidemia associated with antiretroviral therapy for HIV infection. … Tesamorelin is a stabilized synthetic peptide analogue of the hypothalamic peptide, Growth Hormone Releasing Hormone (GHRH) indicated for the reduction of excess abdominal fat in HIV-infected patients
Synonyms: N-[(3E)-1-oxo-3-hexenyl]Somatoliberin (human pancreatic islet), GHRH(1-44)Eribulin
go.drugbank.com/drugs/DB08871ApprovedInvestigationalEribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic
Categories: Heterocyclic Compounds, 1-RingRuxolitinib
go.drugbank.com/drugs/DB08877ApprovedInvestigationalRuxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. … It is a potent and selective inhibitor of JAK1 and JAK2,[A229698] which are tyrosine kinases involved in cytokine signalling and hematopoiesis.
Categories: Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: JAKAVI 5 MG (TABLETS), JAKAVI® 10MG TABLETASLinagliptin
go.drugbank.com/drugs/DB08882ApprovedInvestigationalLinagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes [L9557]. … Linagliptin was approved by the FDA on May 2, 2011[L9557].
Mixtures: GLYXAMBI® 25 MG/ 5 MG, GLYXAMBI® 10 MG/ 5 MGCategories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesLinaclotide
go.drugbank.com/drugs/DB08890ApprovedInvestigationalLinaclotide is a synthetic 14-amino acid cyclic peptide [A260271] and first-in-class guanylate cyclase-C (G-CC) agonist. … [A260276] It is also a homolog of a heat-stable enterotoxin derived from _Escherichia coli_, the first natural ligand that activates GC-C.
Categories: Guanylate Cyclase-C Agonist, Guanylyl Cyclase C AgonistsSynonyms: -GLUTAMYL-L-TYROSYL-L-CYSTEINYL-L-CYSTEINYL-L-ASPARAGINYL-L-PROLYL-L-ALANYL-L-CYSTEINYL-L-THREONYLGLYCYL-L-CYSTEINYL-, CYCLIC (1->6),(2->10),(5->13)-TRIS(DISULFIDE), L-TYROSINE, L-CYSTEINYL-L-CYSTEINYL-L-.ALPHA.Aclidinium
go.drugbank.com/drugs/DB08897ApprovedIt has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012.
Mixtures: DUAKLIR®GENUAIR®340/12MCG/DOSIS.Products: EKLIRA®GENUAIR® 322 MCG/DOSISDolutegravir
go.drugbank.com/drugs/DB08930ApprovedInvestigationalDolutegravir is an HIV-1 integrase inhibitor that blocks the strand transfer step of the integration of the viral genome into the host cell (INSTI). … [L1035] On November 21, 2017, dolutegravir, in combination with rilpivirine, was approved as part of the first complete treatment regimen with only two drugs for the treatment of adults with HIV-1 named
Mixtures: TRIUMEQ® 50 MG / 600 MG / 300 MGCategories: MATE 1 Inhibitors, P-glycoprotein substratesIotroxic acid
go.drugbank.com/drugs/DB08945ApprovedWithdrawnIotroxic acid is a contrast medium molecule.
Categories: X-Ray Contrast Media, Iodinated, Watersoluble, Hepatotropic X-Ray Contrast MediaIopamidol
go.drugbank.com/drugs/DB08947ApprovedInvestigationalIopamidol is a contrast agent developed by Bracco with nonionic, low-osmolar properties.
Categories: X-Ray Contrast Activity, X-Ray Contrast Media, IodinatedProducts: Isovue-M, Isovue-M 200